MX2021008353A - Uso de nitazoxanida en el tratamiento de pacientes con covid-19. - Google Patents

Uso de nitazoxanida en el tratamiento de pacientes con covid-19.

Info

Publication number
MX2021008353A
MX2021008353A MX2021008353A MX2021008353A MX2021008353A MX 2021008353 A MX2021008353 A MX 2021008353A MX 2021008353 A MX2021008353 A MX 2021008353A MX 2021008353 A MX2021008353 A MX 2021008353A MX 2021008353 A MX2021008353 A MX 2021008353A
Authority
MX
Mexico
Prior art keywords
covid
treatment
nitazoxanide
patients
day
Prior art date
Application number
MX2021008353A
Other languages
English (en)
Inventor
José Luis Lauría
Lara Octavio Alejandro Enríquez
Bazán Antonio Rodríguez
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of MX2021008353A publication Critical patent/MX2021008353A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de NTX solo o en combinación con un agente antiinflamatorio y/o un agente activo adicional en la preparación de un medicamento para la prevención o el tratamiento de COVID-19 causada por el coronavirus SARS-CoV-2, en donde dicho medicamento contiene 500 mg de NTX y es administrable 2 a 4 veces al día, hasta una dosis máxima total de 2000 mg al día.
MX2021008353A 2020-09-07 2021-07-08 Uso de nitazoxanida en el tratamiento de pacientes con covid-19. MX2021008353A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/058317 WO2022049414A1 (es) 2020-09-07 2020-09-07 Nitazoxanida para su uso en el tratamiento de covid-19

Publications (1)

Publication Number Publication Date
MX2021008353A true MX2021008353A (es) 2023-05-09

Family

ID=80491659

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023002773A MX2023002773A (es) 2020-09-07 2020-09-07 Nitazoxanida para su uso en el tratamiento de covid-19.
MX2021008353A MX2021008353A (es) 2020-09-07 2021-07-08 Uso de nitazoxanida en el tratamiento de pacientes con covid-19.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2023002773A MX2023002773A (es) 2020-09-07 2020-09-07 Nitazoxanida para su uso en el tratamiento de covid-19.

Country Status (2)

Country Link
MX (2) MX2023002773A (es)
WO (1) WO2022049414A1 (es)

Also Published As

Publication number Publication date
MX2023002773A (es) 2023-04-03
WO2022049414A1 (es) 2022-03-10

Similar Documents

Publication Publication Date Title
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
NZ602512A (en) Treatment of lupus arthritis using laquinimod
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2015103107A (ru) Комбинированная композиция
RU2016143979A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
JP2016505050A5 (es)
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
NZ751972A (en) Treatment of prurigo nodularis
JP2011500589A5 (es)
MX2013003523A (es) Composicion farmaceutica de dosis baja.
JP2020536854A5 (es)
MX2021008353A (es) Uso de nitazoxanida en el tratamiento de pacientes con covid-19.
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
RU2011113733A (ru) Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
JP2019535830A5 (es)
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
BR112022021141A2 (pt) Regime de dosagem para o tratamento de câncer
MX2022012967A (es) Tratamiento de la hidradenitis supurativa.
MX2021008329A (es) Farmaco profilactico o terapeutico para enfermedades neurodegenerativas.
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
WO2022186926A3 (en) Methods for inhibiting coronaviruses using sulforaphane